2022
DOI: 10.3389/fcvm.2022.867002
|View full text |Cite
|
Sign up to set email alerts
|

Higher Mortality Associated With New-Onset Atrial Fibrillation in Cancer Patients: A Systematic Review and Meta-Analysis

Abstract: AimThis research was conducted to evaluate the mortality outcome of cancer patients with new-onset atrial fibrillation. We also aimed to assess if there was any confounding relation between the mortality of these patients and surgical intervention.Materials and MethodsA systemic search was conducted from electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from inception to 7 February 2022. All statistical analyses were conducted in Review Manager 5.4.1. Studies meeting inclusion criteri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(7 citation statements)
references
References 48 publications
0
7
0
Order By: Relevance
“…11,12 New-onset AF in patients with cancer is associated with a higher risk of HF, thromboembolism, bleeding, and mortality. 13–15 Notably, Bruton’s tyrosine kinase (BTK) inhibitors, such as ibrutinib, which are used to treat chronic lymphocytic leukemia and lymphoproliferative malignancies and often used for an extended period of time, are associated with a higher risk of AF due to off-target cardiac effects. 16 In 1 meta-analysis, the risk of AF with use of ibrutinib was 4 times higher compared with that without use of ibrutinib.…”
Section: Af and Specific Patient Groupsmentioning
confidence: 99%
See 1 more Smart Citation
“…11,12 New-onset AF in patients with cancer is associated with a higher risk of HF, thromboembolism, bleeding, and mortality. 13–15 Notably, Bruton’s tyrosine kinase (BTK) inhibitors, such as ibrutinib, which are used to treat chronic lymphocytic leukemia and lymphoproliferative malignancies and often used for an extended period of time, are associated with a higher risk of AF due to off-target cardiac effects. 16 In 1 meta-analysis, the risk of AF with use of ibrutinib was 4 times higher compared with that without use of ibrutinib.…”
Section: Af and Specific Patient Groupsmentioning
confidence: 99%
“…Patients with cancer and AF are older and have higher rates of hypertension, MI, and HF compared with those who do not develop AF. 13–15 The development of perioperative AF has been strongly associated with perioperative complications. 20 In general, patients with cancer and CVD may be undertreated with GDMT or less often referred to specialists for cardiovascular care.…”
Section: Af and Specific Patient Groupsmentioning
confidence: 99%
“…Data pertaining to demographic and clinical characteristics, type of endocarditis (native valve, prosthetic valve), echocardiographic and laboratory investigations, surgical and healthcareassociated procedures six months prior to admission, and hospitalization progress charts were retrieved. Patients were enrolled upon being diagnosed with IE by use of the modified Duke criteria [29, 40] and Charlson's comorbidity index [13]. Laboratory evaluation was performed using inflammation tests, complete blood count (CBC), erythrocyte sedimentation rate, C-reactive protein and biochemical parameters.…”
Section: Methodsmentioning
confidence: 99%
“…However, atenolol can also decrease airway function in patients with asthma or chronic obstructive pulmonary disease when administered in large doses. Therefore, the selection of the atenolol dose still needs to be clarified [17,18]. In summary, there are many drugs for the clinical treatment of angina pectoris, and the selection of a scientific and efficient drug combination regimen is currently a problem that needs to be solved.…”
Section: Introductionmentioning
confidence: 99%